Pazopanib + Abexinostat for Kidney Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking any prohibited medications at least 7 days or 5 half-lives before starting the study drug. However, the protocol does not specify which medications are prohibited, so it's best to discuss your current medications with the study team.
What data supports the effectiveness of the drug Pazopanib for kidney cancer?
Is the combination of Pazopanib and Abexinostat safe for humans?
What makes the drug Pazopanib unique for kidney cancer treatment?
Pazopanib is unique because it is an oral drug that targets multiple pathways involved in cancer growth, specifically inhibiting the vascular endothelial growth factor receptors (VEGFR), which play a key role in the formation of blood vessels that supply tumors. This makes it different from other treatments that may not target these specific pathways or are not taken orally.12368
What is the purpose of this trial?
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Research Team
Pamela Munster, M.D.
Principal Investigator
University of California, San Francisco
Rahul Aggarwal, M.D.
Principal Investigator
University of California, San Francisco
Eligibility Criteria
Adults with advanced kidney cancer that hasn't spread to the brain can join this study. They should have clear cell renal carcinoma, measurable disease, and no prior treatments with certain cancer drugs. Good blood counts and organ function are needed, and they must be at least two weeks out from previous treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pazopanib plus abexinostat or pazopanib plus placebo in 28-day cycles until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Crossover
Participants in the placebo arm may cross over to receive pazopanib plus abexinostat upon disease progression
Treatment Details
Interventions
- Abexinostat
- Pazopanib
Pazopanib is already approved in United States, European Union, China for the following indications:
- Advanced renal cell carcinoma (kidney cancer)
- Soft tissue sarcoma
- Advanced renal cell carcinoma (kidney cancer)
- Soft tissue sarcoma
- Metastatic renal cell carcinoma (mRCC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xynomic Pharmaceuticals, Inc.
Lead Sponsor